Chief Executive Officer
Our Chief Executive Officer manages all business operations and provides a vision for the future of EncepHeal Therapeutics, Inc. Lazarus previously served as project manager for the lead generation program at PatientStar LLC. He graduated from Wake Forest University with his M.A. in Management in 2015 and his B.S. in Biology in 2014.
Chief Scientific Officer
As Chief Scientific Officer, Dr. Rahimi oversees the scientific development of each asset and is in charge of identifying new discoveries and technologies for incorporation into our business. Dr. Rahimi earned a B.S. in Biochemistry from the University of St. Thomas, a M.Sc. in Pharmacology from the University of Minnesota, and a Ph.D. in Integrative Physiology and Pharmacology from Wake Forest School of Medicine. His thesis research concentration focused on a potential therapy for the mitigation of chemotherapeutic cardiotoxicity.
Chief Research Officer
As Chief Research Officer, Dr. Childers will lead the development of EncepHeal Therapeutics psychostimulant addiction therapeutics. With over 30+ years of experience he is widely regarded as a top expert in the field of biochemical neuropharmacology. Since 1999 his research has had a focus on the identification of potential medications to treat cocaine addiction. As part of that effort, his laboratory has screened over 600 novel compounds at brain target receptors to identify logical candidates for medication development.
Board of Directors & Business Advisors
Mr. Robert Anderson is an executive with a proven track record of accomplishments in the financial, high-tech, and medical industries. He is a skilled and resourceful manager with broad experience working with senior executives and cross-functional teams. Mr. Anderson previously worked with PointDx, Inc. and served as CEO of GreatWall Systems, Inc. where he raised more than $850K in government grants and $1.2M from private investors. He provides experience in assessing potential strategic initiatives, investment opportunities, mergers and acquisitions, distribution agreements, vendor financial reviews, and joint ventures. Mr. Anderson currently serves as CEO of Causa Research, Inc. where he manages all aspects of the company (including raising capital, managing day-to-day activities, and managing sales and partnerships). Mr. Anderson earned his B.S. in Mathematics with an emphasis in Computer Science from Berea College and his M.B.A. from Wake Forest University.
Dr. Peter Sheldrake is an Adjunct Professor of Innovation and Global Business at Wake Forest University. Until recently he was an Adjunct Professor at RMIT University in Melbourne, Australia, where he served as Professor of Business Entrepreneurship for fourteen years. In that role, he was responsible for teaching and conducting research in innovation and entrepreneurship, global business, business strategy, and leadership. In addition to having developed and instructed several executive education classes and university postgraduate courses, Dr. Sheldrake has been a consultant for companies, small businesses, and not-for-profits across the U.S., Australia, and Southeast Asia. He earned his B.A., M.A., and M.Sc. from the University of Cambridge and his Ph.D. from RMIT University.
Scientific Advisory Board & Collaborators
Dr. Martell has over 15 years of experience in the pharmaceutical/biotechnology industry as a drug developer, strategic advisor, and scientific consultant. She has deep expertise in therapeutic drug development and has brought complex protein biologics, biosimilars, combined drug devices, and therapeutic vaccines through various stages of development while being facile in understanding the Global Regulatory landscape and the requirements to bring medicines through to approval with the appropriate value to patients, physicians, and payers alike. She has work in varied therapeutic areas including oncology, immuno-oncology, rheumatology, pain, addiction, orphan diseases, CNS, cardiovascular, and women’s health. She is currently leading her consulting practice, BAM Consultants, LLC, where she has advised clients since 2013. From 2015 to present she served as the Senior Vice President of New Product Development and Chief Medical Officer of Juniper Pharmaceuticals, a public company with a focus on women’s health therapeutics. Currently, Dr. Martell still actively practices clinical internal medicine part-time at Yale and serves as an Entrepreneur-In-Residence for Yale’s Office of Cooperative Research helping guide Yale innovators on the prospects for their patented technologies, therapeutics, devices, and diagnostics. This work coupled with her deep industry experience adds value and perspective in understanding marketplace dynamics and continued unmet medical need.
Her prior work has included overseeing product development and medical affairs activities for numerous pharmaceutical companies, including Purdue Pharma and several business units within Pfizer Worldwide’s biopharmaceutical business. At Purdue Pharma, Dr. Martell led and built a new medical affairs organization to support the in-line and developing pain medicines. As the Biosimilars Medical Head at Pfizer, she was responsible for clinical development and medical affairs activities of the portfolio in that newly created business. She also held senior clinical development roles at other business units within Pfizer’s biopharmaceutical businesses. She began her clinical investigation career at Yale with a Career Development Award and as a Faculty Auditor in the Robert Wood Johnson Clinical Scholar conducting the first therapeutic cocaine vaccine trial for adjunctive treatment for cocaine dependence.
Dr. Martell holds a Bachelor of Science in microbiology from Cornell University, a Master of Arts in molecular immunology from Boston University, and a Doctor of Medicine degree from The Chicago Medical School. She completed her internship and residency in internal medicine, was also an Internal Medicine Chief Resident. She is board certified in both internal and addiction medicine.
Dr. Amy Hauck Newman has published 245 peer-reviewed manuscripts and is widely regarded as an expert in the field of medicinal chemistry. She currently serves as Acting Scientific Director of the National Institute on Drug Abuse (NIDA) Intramural Research Program and Chief of the Medications Discovery Research Branch and Medicinal Chemistry Sections of NIDA. She has designed several research tools to better evaluate drug-receptor interactions and study how molecular changes influence behavior. In recent years, her lab has synthesized novel compounds that target monoamine transporters and receptors to treat addictions. She is the lead inventor of EncepHeal's first pharmacotherapies to treat cocaine addiction. Dr. Newman earned her B.S. in Chemistry from Mary Washington College and her Ph.D. in Medicinal Chemistry from the Medical College of Virginia where she designed and synthesized novel amphetamine analogs. Dr. Newman completed her postdoctoral training under Dr. Kenner C. Rice at the Laboratory of Medicinal Chemistry at the NIH and worked at the Walter Reed Army Institute of Research before she initiated the Medicinal Chemistry Program at NIDA.